Appointments: Sanofi, MSD, Pandion, Orchard, Redx, Glythera, Inotrem
Executive Summary
Companies filling positions include Sanofi, with a new head of business transformation, and MSD Research Laboratories, with a leader for its new London early discovery facility. There is new leadership for Pandion Therapeutics, and further C-suite appointments at Orchard Therapeutics, Redx Pharma, Glythera and Inotrem.
Sanofi has appointed Dominique Carouge executive vice president head of business transformation, effective Feb. 15, 2018. He will join the executive committee and take charge of accelerating the French company's transformation. Carouge has served as deputy chief financial officer and head of finance operations and group controlling since the beginning of 2016, and has held other leadership roles at the company, which he joined in 1991.
Dominique Carouge, Sanofi's new head of business transformation Sanofi
Fiona Marshall is to lead MSD Research Laboratories' new discovery research facility in London. MSD Research Laboratories is known as Merck & Co. Inc. in the US and Canada. Marshall was previously executive vice president and chief scientific officer at Sosei Group Corp., which in 2015 acquired the company she had co-founded, Heptares Therapeutics Ltd. An expert in G-Protein Coupled Receptor (GPCR) biology, she has more than 25 years' experience in drug discovery, and formerly headed the department of molecular pharmacology at GlaxoSmithKline PLC.
Fiona Marshall will head MSD's London research facility MSD Research Laboratories
Pandion Therapeutics Inc. has been launched with new leadership and a $58m series A financing. The company, which develops bispecific antibodies for localized immunomodulation to treat autoimmune and inflammatory diseases, has appointed co-founders Anthony Coyle CEO and Jo Viney as chief scientific officer. Coyle was previously senior vice president at Pfizer Inc. and vice president and global head of inflammation biologics at MedImmune. Viney was previously senior vice president of drug discovery and vice president of immunology research for Biogen Inc. Fellow co-founders of Pandion include Alan Crane, partner at Polaris Partners, and David Sachs, a clinician and expert in transplantation and immunology. Joining Crane and Coyle on the company's board of directors are Carlo Rizzuto, partner at Versant Ventures, Mitchell Mutz, investment director at Roche Venture Fund, and Vikas Goyal, principal at SR One.
Gene therapy specialist Orchard Therapeutics has appointed Frank Thomas to the newly created position of chief financial officer and chief business officer. Until recently, Thomas served as president and chief operating officer of AMAG Pharmaceuticals Inc.
Redx Pharma PLC has appointed Andrew Saunders as chief medical officer, as the company prepares to take its lead compound, the oral small-molecule porcupine inhibitor RXC004 for cancer, into its first Phase I study. Saunders joins Lytix Biopharma AS, a Norwegian immuno-oncology firm, where he was also CMO. He was previously medical director at Bioenvision Limited, later acquired by Genzyme, and global clinical science leader for rituximab at Roche.
Robert Lutz has been appointed chief scientific officer of Glythera Ltd. of the UK, which is developing antibody drug conjugates (ADCs) aimed at difficult to treat tumors. Lutz was responsible for all early-stage ADC development programs at ImmunoGen Inc., where he was vice president of translational research and development. Also, Jon Roffey of Cancer Research Technology Ltd., Cancer Research UK's commercial partnerships arm, has joined Glythera's scientific advisory board. Roffey is a medicinal chemist by training, with responsibility for forging drug-discovery alliances between academia and industry at CRT.
French immunomodulation firmInotrem SA has appointed as chief operating officer Martin Koch, former CFO of French immunotherapy developer Genticel, which merged with GenKyoTex in 2017.
Thank you for reading this article! Please help us to better help you, by taking our Pharma Feedback survey . Not only will your participation help steer our efforts to continually improve the content and delivery of our products – you’ll also have a chance to win one of four Amazon gift cards valued at $100 (US).